Blueprint Medicines (BPMC) investor relations material

Company overview and strategic focus

• Focused on developing life-changing medicines for diseases related to mast cell biology, evolving from an oncology heritage.

• Lead product AYVAKIT treats systemic mastocytosis (SM), a rare disease caused by a mast cell mutation.

• Pipeline includes programs targeting wild-type mast cells for type 2 inflammatory diseases.

• Strong financial position, aiming for self-sustainability and continued growth.

AYVAKIT commercial performance and market opportunity

• Approved in three indications: a GIST subtype, advanced SM, and indolent SM (ISM), with ISM being the largest market.

• ISM approval in mid-2023 opened a significant growth opportunity, with an estimated 60,000 US patients, 90-95% of whom have ISM.

• 2025 revenue guidance is $700–$720 million, with a target of $2 billion in global revenue by 2030.

• Franchise opportunity projected at $4 billion+, with the US expected to contribute 70–80% at peak.

Market penetration and growth strategies

• Achieving $2 billion revenue by 2030 requires treating only a minority of diagnosed patients, about 6,000 in the US.

• Focus on expanding prescriber experience and direct-to-consumer digital engagement to drive patient demand.

• Recurring revenue base supported by long therapy duration, with patients modeled to stay on treatment for three or more years.

• Sophisticated data operations and targeted sales efforts prioritize high-need patient locations.